Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts


Vascular Dementia 2020

Neuroscience conferences inviting you to “2nd World Conference on Vascular Dementia & Movement Disorders” during August 26-27, 2020, at Singapore.

Vascular dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain.

Factors that increase your risk of heart disease and stroke — including diabetes, high blood pressure, high cholesterol and smoking — also raise your vascular dementia risk. Controlling these factors may help lower your chances of developing vascular dementia

Vascular dementia is the second-most-common type of dementia in the United States and Europe in the elderly; however it is the most common form in some parts of Asia. The incidence of the illness is 1.5% in Western countries and just about 2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in Europe and 15% in Latin America. The prevalence of dementia is 9 times higher in patients who have had a stroke than in controls. 25% of stroke patients develop new-onset dementia within 1 year of their stroke. The relative risk of incident dementia is 5.5% within 4 years of suffering a stroke.

Benefits of attending!

 Benefits to Attend Vascular Dementia 2020

  • Learning in a New Space

  • Learning with the experts

  • Novel techniques to benefit your research

  • Lectures by active practitioners

  • Networking with new people within your field

  • Keynote forums by Prominent Professors, Doctors and Physicians

  • Poster presentations by Young Researchers

  • Learning about facts and statistics to better understand the market and industry

Target Of Audience:

  • Business ambassadors

  • Industrial Frontrunners

  • Stroke Scientists, Neuro Oncologists

  • CEO's and Directors

  • Neurologist

  • Neurosurgeons

  • Psychiatrist

  • Neuroscientist

  • Head of department

  • Professors and Students from Academia in the research of neurological disorders

Sessions And Tracks


Dementia is a wide category of brain diseases that cause an abiding and often moderate decrease in the capability to think and recall that is acute enough to affect a person's normal functioning. The most usual category of dementia is Alzheimer's disease, which makes up 50% to 70% of cases. The indications of dementia differ across types and stages of the diagnosis. The most usual affected areas are memory, visual-spatial, problem solving, language and attention. There is no known treatment for dementia. Cholinesterase inhibitors such as donepezil are frequently used and may be beneficial in moderate disorder.

Vascular Dementia and Stroke

Vascular dementia is dementia caused by difficulty in the supply of blood to the brain, typically a series of minor strokes, leading to worsening cognitive decline that occurs step by step. The term refers to a syndrome consisting of a complex interaction of cerebrovascular disease and risk factors that lead to changes in the brain structures due to strokes and lesions, and resulting changes in cognition. The temporal relationship between a stroke and cognitive deficits is needed to make the diagnosis. People with vascular dementia present with progressive cognitive impairment, acutely or sub acutely as in mild cognitive impairment, frequently step-wise, after multiple cerebrovascular events (strokes).

Amyloid Imaging in Dementia

Amyloid-related imaging abnormalities (ARIA) are abnormal differences seen in neuroimaging of Alzheimer's disease patients, associated with amyloid-modifying therapies, particularly human monoclonal antibodies such as aducanumab. There are two types of ARIA - ARIA-E and ARIA-H. The phenomenon was first seen in trials of bapineuzumab.

Alzheimer’s disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, and loss of motivation, not managing self-care, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death

Neurodegenerative Diseases

Neuro degeneration is the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases – including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease – occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells. As research progresses, many similarities appear that relate these diseases to one another on a sub-cellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate many diseases simultaneously

Brain Diseases

Central nervous system problems are also known as central nervous system disorders. These are the neurological problems that affect the function and structure of the brain and spinal cord, which form the central nervous system. Signs are like persistent headache; face pain, band and legs pain, inability to concentrate and slurred speech etc.

Ageing and Dementia

Aging is a main risk element for most common neurodegenerative problems, including mild cognitive impairment, dementias including cerebrovascular disease, Alzheimer's disease, Lou Gehrig's disease, and Parkinson's disease. While much research has focused on problems of aging, there are less informative studies on the molecular biology of the aging brain in the lack of neurodegenerative disease or the neuropsychological discription of healthy older adults. However, research suggests that the aging process is associated with several structural, chemical, and functional changes in the brain as well as a host of neurocognitive changes.

Dementia Care Management

Dementia care management is nothing but care provided to dementia patients at home/hospital. In-home care includes a wide range of services provided in the home, rather than in a hospital or care facility. It can allow a person with Alzheimer's or other dementia to stay in his or her own home. It also can be of great assistance to caregivers. It can allow a person with Alzheimer's or other dementia to stay in his or her own home.

Dementia Nursing

Dementia nurses can provide treatment, support and care for people with dementia and mental health problems. They might assess you at your home, and they advise you and your careers on ways of improving your health and quality of life. Dementia nurses do not normally carry out physical tasks like changing bandages or keeping saline etc. Dementia nurses will do psychological activities to care dementia patients.

Diagnosis and treating Dementia

Diagnosing dementia and its categories can be challenging. People have dementia when they have analytical impairment and lose their capability to do daily functions, such as driving safely, taking medications, taking food time on time etc. To diagnose the reason of dementia, the physician must recognize the pattern of the dropping of skills, function and understand what a person is still capable to do. Recently, biomarkers are available to make a more exact diagnosis of Alzheimer's problem. Doctor will examine your medical condition, history, symptoms and conduct a physical/mental examination.


Neuropharmacology will give information about how drugs affect cellular function in the nervous system, and the neural mechanisms through which they influence behavior. There are two main branches of neuropharmacology: behavioral and molecular. Behavioral neuropharmacology focuses on the study of how drugs affect human behavior (neuro psychopharmacology), including the study of how drug dependence and addiction affect the human brain.  Molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with the overall goal of developing drugs that have beneficial effects on neurological function.

Novel therapeutics for Dementia:

Novel Therapeutic Technology is a leading pioneer in the development of sophisticated and practical drug delivery systems. NTT's Ethosome technology provides the means to significantly enhance drug penetration of topical delivery applications, exponentially increasing therapeutic efficiency. With worldwide recognized drugs combined with NTT know-how, Pharmaceutical companies are able to introduce new and better drugs to the market, thus greatly reducing side effects, improving patient compliance, and increasing the patient’s quality of life.

Neuro Oncology and CNS:

It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects.

To Collaborate Scientific Professionals around the World

Conference Date August 26-27, 2020

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Alzheimers Disease & Parkinsonism Journal of Neurological Disorders

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by